

PATENT
09/849,022
Docket 091/005

REMARKS

This paper follows the Amendments under 37 CFR § 1.116 filed September 10, 2004; and April 7, 2005, which have both been entered into the file.

By way of this amendment, only claims 8 and 9 have been changed. The markings to the claims shown above reflect changes to the claims as they were presented in the Amendment filed April 7, 2005. The amendments to the claims are supported by the claims as previously presented, and throughout the specification, and introduce no new matter into the application.

Further consideration and allowance of the application is respectfully requested.

Claims 8, 9, 13, 15, 16, 18, 19, and 25-36 stand rejected under the enablement requirements of § 112 ¶ 1. Base claims 8 and 9 are now amended to refer to culturing the hES cells essentially without feeder cells, but in a medium conditioned by fibroblast feeder cells. Withdrawal of this rejection is respectfully requested.


The application is believed to be in condition for allowance, which is respectfully requested. Should the Examiner determines that there are other matters to be addressed, applicant hereby requests a further interview by telephone.

PATENT
09/849,022
Docket 091/005

Authorization is given in the accompanying papers for requesting continued examination under 37 CFR § 1.114.

No other fee is believed due for entry or consideration of this paper. Nevertheless, should the Patent Office determine that an extension of time or any other relief is required for further consideration of this application, applicant hereby petitions for such relief, and authorizes the Commissioner to charge the cost of such petitions and other fees due in connection with the filing of these papers to Deposit Account No. 07-1139, referencing the docket number indicated above.

Respectfully submitted,



J. Michael Schiff
Registration No. 40,253

GERON CORPORATION
230 Constitution Drive
Menlo Park, CA 94025
Telephone: (650) 473-7715
Fax: (650) 473-8654

July 19, 2005

21 AF